SFDA Alerts On Adverse Reactions Of Aciclovir And Cephradine
This article was originally published in PharmAsia News
Executive Summary
China's State FDA has alerted health care professionals, pharmaceutical manufacturers and distributors and the public about adverse reactions associated with antiviral aciclovir and antibiotic cephradine. According to figures from the National Center for ADR Monitoring, problems attributed to the two drugs - acute renal impairment and blood in urine - are still outstanding. SFDA reminds physicians to conduct full risk-benefit analysis when choosing drugs, paying especially close attention to the adverse effects caused by aciclovir and cephradine. The relevant manufacturers should conduct in-depth research into the mechanisms of the drug-caused impairment, evaluate the overall risk-benefit of the two medicines and adopt timely effective measures to reduce recurrence of adverse incidents in similar drugs. (Click here for more - Chinese Language)
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.
EU Must Crack Down Harder On Fake Medical Devices, Says Innovator
Counterfeit copies of LifeVac Europe’s anti-choking devices have been registered on the EU’s EUDAMED database and continue to be sold on third-party platforms. Medtech Insight asked director of sales and marketing Matthew Banagan how the company deals with fake devices and what the authorities must do.